Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy (Systemic and Cerebral) and Safety of PEMbrolizumab PD-L1-positive (More Than 50% of Tumor Cells), Advanced Non-small-cell Lung Cancer : A Study of Real Life in Brittany .

NCT05321212 is registered in ClinicalTrials.gov with University Hospital, Brest as lead sponsor.

NCT NCT05321212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05321212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy (Systemic and Cerebral) and Safety of PEMbrolizumab PD-L1-positive (More Than 50% of Tumor Cells), Advanced Non-small-cell Lung Cancer : A Study of Real Life in Brittany .
Lead sponsor
University Hospital, Brest
Phase
Observational
Overall status
Completed
Start date
January 2, 2019
Completion date
March 2, 2019
Enrollment
108 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, immunotherapy